


PHARMACEUTICAL 2023

Nkarta Inc. Rank 116 of 446





PHARMACEUTICAL 2023

Nkarta Inc. Rank 116 of 446

The relative strengths and weaknesses of Nkarta Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nkarta Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 47% points. The greatest weakness of Nkarta Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 52% points.

The company's Economic Capital Ratio, given in the ranking table, is 183%, being 140% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	360,688
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	22,046
Liabilities, Non-Current	78,685
Other Assets	50,342
Other Compr. Net Income	-529
Other Expenses	0
Other Liabilities	0
Other Net Income	5,118
Other Revenues	0
Property and Equipment	61,908
Research and Development	90,897
Selling, General and Administrative Expense	28,058

Output Variable	Value in 1000 USD
Assets	472,938
Liabilities	100,731
Expenses	118,955
Revenues	0
Stockholders Equity	372,207
Net Income	-113,837
Comprehensive Net Income	-114,102
Economic Capital Ratio	183%

